XBiotech (NASDAQ:XBIT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.17 and traded as low as $2.80. XBiotech shares last traded at $2.87, with a volume of 37,766 shares changing hands.

XBiotech Price Performance

The business's 50 day moving average price is $3.16 and its 200 day moving average price is $4.57. The firm has a market cap of $86.74 million, a PE ratio of -2.63 and a beta of 0.98.

XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) EPS for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG acquired a new position in XBiotech during the fourth quarter worth about $120,000. Northern Trust Corp boosted its holdings in shares of XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock worth $835,000 after purchasing an additional 27,909 shares during the last quarter. Geode Capital Management LLC grew its position in shares of XBiotech by 5.1% in the third quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company's stock valued at $3,496,000 after purchasing an additional 22,059 shares in the last quarter. Barclays PLC increased its holdings in shares of XBiotech by 247.4% in the third quarter. Barclays PLC now owns 26,343 shares of the biopharmaceutical company's stock valued at $204,000 after purchasing an additional 18,761 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of XBiotech in the fourth quarter valued at approximately $58,000. Hedge funds and other institutional investors own 55.70% of the company's stock.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.